Total parenteral nutrition in the surgical patient: a meta-analysis
…, M Montalvo, S MacDonald, L Keefe, XY Su… - Canadian Journal of …, 2001 - canjsurg.ca
Objective: To examine the relationship between total parenteral nutrition(TPN) and complication
and death rates in surgical patients. Data sources: A computer search of published …
and death rates in surgical patients. Data sources: A computer search of published …
Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to …
…, PJ Rosenfeld, HA Strong, M Stur, XY Su… - American journal of …, 2003 - europepmc.org
Purpose To determine whether differences in baseline lesion size and visual acuity might
explain differing results found in three different lesion compositions (predominantly classic, …
explain differing results found in three different lesion compositions (predominantly classic, …
Should immunonutrition become routine in critically ill patients?: A systematic review of the evidence
DK Heyland, F Novak, JW Drover, M Jain, X Su… - Jama, 2001 - jamanetwork.com
ContextSeveral nutrients have been shown to influence immunologic and inflammatory
responses in humans. Whether these effects translate into an improvement in clinical outcomes …
responses in humans. Whether these effects translate into an improvement in clinical outcomes …
Glutamine supplementation in serious illness: a systematic review of the evidence
…, DK Heyland, A Avenell, JW Drover, X Su - Critical care …, 2002 - journals.lww.com
Objective To examine the relationship between glutamine supplementation and hospital
length of stay, complication rates, and mortality in patients undergoing surgery and …
length of stay, complication rates, and mortality in patients undergoing surgery and …
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
…, P Soucek, HA Strong, A Wenkstern, XY Su… - … (Chicago, Ill.: 1960), 2005 - europepmc.org
Objective To compare the treatment effect and safety of photodynamic therapy with verteporfin
using a standard (SF) or reduced (RF) light fluence rate with that of placebo therapy in …
using a standard (SF) or reduced (RF) light fluence rate with that of placebo therapy in …
Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfinand red light–emitting diodes: two-year results evaluating tumor response and cosmetic …
…, N Provost, A Chan, H Neyndorff, XY Su… - Archives of …, 2004 - jamanetwork.com
Background Efficient treatment of patients with multiple synchronous nonmelanomaskin
cancers represents a therapeutic challenge. Objective To study the safety and efficacy of …
cancers represents a therapeutic challenge. Objective To study the safety and efficacy of …
A phase I clinical trial of guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer: clinical, pharmacokinetic, and pharmacodynamic analyses
…, S Jueliger, A Oganesian, S Naim, XY Su… - Clinical Cancer …, 2018 - AACR
Purpose: Epigenetic changes are implicated in acquired resistance to platinum. Guadecitabine
is a next-generation hypomethylating agent (HMA). Here, we report the clinical results, …
is a next-generation hypomethylating agent (HMA). Here, we report the clinical results, …
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical …
…, A Reaves, PJ Rosenfeld, A Strong, XY Su… - Retina (Philadelphia …, 2004 - europepmc.org
Purpose We sought to evaluate the detailed safety profile of photodynamic therapy with
verteporfin in patients with subfoveal choroidal neovascularization (CNV) caused by age-related …
verteporfin in patients with subfoveal choroidal neovascularization (CNV) caused by age-related …
A phase I study of ASTX660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma
…, R Ferraldeschi, H Keer, A Oganesian, XY Su… - Clinical Cancer …, 2020 - AACR
Purpose: This first-in-human, phase I study evaluated ASTX660, an oral, small-molecule
antagonist of cellular/X-linked inhibitors of apoptosis proteins in patients with advanced solid …
antagonist of cellular/X-linked inhibitors of apoptosis proteins in patients with advanced solid …
[HTML][HTML] Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
Background Guadecitabine is a novel DNA methyltransferase (DNMT) inhibitor with improved
pharmacokinetics and clinical activity in a subset of patients with relapsed/refractory acute …
pharmacokinetics and clinical activity in a subset of patients with relapsed/refractory acute …